Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Hormone pill may cut heart risk in perimenopause, small study suggests

NCT ID NCT07609043

Disease control Sponsor: Universidad de Guanajuato Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase 3 trial tested whether taking 50 mg of prasterone (DHEA) daily for 2 months could improve cardiometabolic indicators in perimenopausal women. The study enrolled 25 women and measured changes in insulin resistance and lipid levels. The goal is to find a way to prevent metabolic and cardiovascular complications that often arise during the transition to menopause.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
prasterone (DHEA)
What this could lead to
If successful, this could point toward a hormone therapy to reduce cardiometabolic risk during perimenopause.
What could go wrong
This is a very small, completed Phase 3 trial with only 25 participants, so results may not apply broadly. DHEA can have hormonal side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

25 people

The number who actually took part.

Started

Jan 2020

Finished

Jan 2021

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

42 years and older

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * with no history of breast cancer, HRT, morbid obesity, cardiovascular disease, or DM. Exclusion Criteria: \-

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardio metabolic risk are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardio metabolic risk

Contacts and locations

Locations

  • Universidad de Guanajuato

    Mexico City, Guanajuato, 36000, Mexico

More trials for these conditions

Other studies related to the condition(s) this trial covers.